Abstract
This study was designed to show the advantages of using the combination of metformin and rosiglitazone over using each drug alone in treatment of women with polycystic ovary syndrome (PCOS).Forty four women with PCOS were classified into 3 groups , group 1 received rosiglitazone (4mg/day) for 3 months , group ΙΙ received metformin ( 1500 mg/day)for three months and groupΙΙΙ received the combination ( rosiglitazone 4mg/day + metformin 1500 mg/day) for the same period of treatment . The blood samples were drawn before treatment and after 3 months of treatment . The fasting serum glucose , insulin , progesterone , testosterone , leutinizing hormone were measured before and after treatment. The reduction of serum insulin , glucose ,homostasis model assessment of insuline resistance ( HOMA-IR) , LH and testosterone levels were greater in the group received the combination of rosiglitazone with metformin than that those taken each one alone. Testosterone levels decreased significantly (P<0.05) from baseline level 1±0.04ng/ml to 0.073±0.32ng/ml after treatment with combination.The rate of ovulation is 29.4%,36.4% , 62.5% in rosiglitazone , metformin and combination of both, respectively.The combination of rosiglitazone with metformin has more beneficial effect on ovulation rate. 
 Key words: polycystic ovary syndrome, rosiglitazone, metformin, ovulation rate .
Highlights
Polycystic ovary syndrome (PCOS) is the most common abnormality in women during reproductive age, it is a hetrogenous disorder of uncertain etiology [1]
The combination of metformin and rosiglitazone reduced the levels of serum insulin, glucose, HOMA-IR, LH and testosterone which are more than that produced by rosiglitazone or metformion alone(P
In present study, rosiglitazone and metformin treatment improved insulin resistance because there was an improvement in fasting insulin and fasting glucose levels, similar results were reported by other studies [27,28]
Summary
Polycystic ovary syndrome (PCOS) is the most common abnormality in women during reproductive age, it is a hetrogenous disorder of uncertain etiology [1]. It is characterized by chronic anovulation and hyperandrogenism [2]. Affecting approximately 5-10 % of reproductive age women. There is some data to suggest that insulin enhances the effect of LH on preovulatory ovarian follicle arrest [5]. It is possible that hyperinsulinemia due to insulin resistance drives the LH affect on ovarian theca cells to cause androgen excess which are intrinsically programmed to produce more androgens [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Iraqi Journal of Pharmaceutical Sciences ( P-ISSN: 1683 - 3597 , E-ISSN : 2521 - 3512)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
